AZ reveals Phase III selumetinib miss in differentiated thyroid cancer

AstraZeneca plc (LSE:AZN; NYSE:AZN) disclosed in its 2Q18 earnings that it discontinued development of selumetinib to treat differentiated thyroid cancer after the candidate missed the primary endpoint in the Phase III ASTRA trial

Read the full 335 word article

User Sign In